HomeCompareCSBTF vs EPRT

CSBTF vs EPRT: Dividend Comparison 2026

CSBTF yields 7.18% · EPRT yields 3.92%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 EPRT wins by $31.2K in total portfolio value· pulled ahead in Year 4
10 years
CSBTF
CSBTF
● Live price
7.18%
Share price
$27.85
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.2K
Annual income
$1,132.80
Full CSBTF calculator →
EPRT
EPRT
● Live price
3.92%
Share price
$30.77
Annual div
$1.21
5Y div CAGR
29%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$63.4K
Annual income
$12,840.73
Full EPRT calculator →

Portfolio growth — CSBTF vs EPRT

📍 EPRT pulled ahead of the other in Year 4

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSBTFEPRT
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSBTF + EPRT cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSBTF pays
EPRT pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSBTF
Annual income on $10K today (after 15% tax)
$610.41/yr
After 10yr DRIP, annual income (after tax)
$962.88/yr
EPRT
Annual income on $10K today (after 15% tax)
$332.87/yr
After 10yr DRIP, annual income (after tax)
$10,914.62/yr
At 15% tax rate, EPRT beats the other by $9,951.74/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSBTF + EPRT for your $10,000?

CSBTF: 50%EPRT: 50%
100% EPRT50/50100% CSBTF
Portfolio after 10yr
$47.8K
Annual income
$6,986.76/yr
Blended yield
14.62%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EPRT right now

CSBTF
No analyst data
Altman Z
15.0
Piotroski
4/9
EPRT
Analyst Ratings
1
Strong
17
Buy
3
Hold
1
Sell
Consensus: Buy
Price Target
$35.50
+15.4% upside vs current
Range: $33.00 — $37.00
Altman Z
1.8
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSBTF buys
0
EPRT buys
0
No recent congressional trades found for CSBTF or EPRT in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSBTFEPRT
Forward yield7.18%3.92%
Annual dividend / share$2.00$1.21
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%29%
Portfolio after 10y$32.2K$63.4K
Annual income after 10y$1,132.80$12,840.73
Total dividends collected$9.3K$37.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: CSBTF vs EPRT ($10,000, DRIP)

YearCSBTF PortfolioCSBTF Income/yrEPRT PortfolioEPRT Income/yrGap
1$11,418$718.13$11,205$505.18+$213.00CSBTF
2$12,984$766.33$12,672$682.46+$312.00CSBTF
3$14,707$814.40$14,490$930.48+$217.00CSBTF
4← crossover$16,599$862.14$16,786$1,282.69$187.00EPRT
5$18,670$909.37$19,753$1,791.56$1.1KEPRT
6$20,933$955.93$23,677$2,541.64$2.7KEPRT
7$23,400$1,001.68$29,008$3,672.99$5.6KEPRT
8$26,084$1,046.47$36,463$5,425.08$10.4KEPRT
9$29,000$1,090.21$47,238$8,221.57$18.2KEPRT
10$32,163$1,132.80$63,385$12,840.73$31.2KEPRT

CSBTF vs EPRT: Complete Analysis 2026

CSBTFStock

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.

Full CSBTF Calculator →

EPRTREIT

Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical and dental services, convenience stores, equipment rental, entertainment, early childhood education, grocery, and health and fitness on a long-term basis. As of December 31, 2021, it had a portfolio of 1, 451 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is headquartered in Princeton, New Jersey.

Full EPRT Calculator →
📬

Get this CSBTF vs EPRT comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSBTF vs SCHDCSBTF vs JEPICSBTF vs OCSBTF vs KOCSBTF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.